Health ❯ Healthcare

Adverse Events

Drug Safety Vaccine Safety Treatment-Related Adverse Events Medication Safety Safety Profile Safety Profiles Clinical Safety Clinical Trials Treatment-Emergent Adverse Events Treatment Safety

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

Regulators cited LITESPARK-022 results showing reduced recurrence risk, with specific dosing and safety guidance issued.

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

Spyre Drug Meets Midstage Target in Ulcerative Colitis, Stock Rallies

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Praxis Drug Succeeds in Two Phase 3 Essential Tremor Trials, FDA Filing Planned

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Once-Monthly Subcutaneous Amivantamab Plus Lazertinib Shows High Response in Untreated EGFR‑Mutated NSCLC

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care